Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opening Session Panel Discussion

Advertisement

Advertisement




Nov
28
Today In Oncology
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo